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ABSTRACT
The molecular mechanisms of hepatocellular carcinoma (HCC) carcinogenesis 
are still not fully understood. DNA repair defects may influence HCC risk. The aim of 
the study was to look for potential genetic variants of DNA repair genes associated 
with HCC risk among patients with alcohol- or viral-induced liver disease. We 
performed four case-control studies on 2,006 European- (Derivation#1 and #2 
studies) and African-ancestry (Validation#1 and #2 studies) patients originating 
from several cohorts in order to assess the association between genetic variants on 
DNA repair genes and HCC risk using a custom array encompassing 94 genes. In the 
Derivation#1 study, the BRIP1 locus reached array-wide significance (Chi-squared 
SV-Perm, P=5.00×10–4) among the 253 haplotype blocks tested for their association 
with HCC risk, in patients with viral cirrhosis but not among those with alcoholic 
cirrhosis. The BRIP1 haplotype block included three exonic variants (rs4986763, 
rs4986764, rs4986765). The BRIP1 ‘AAA’ haplotype was significantly associated 
with an increased HCC risk [odds ratio (OR), 2.01 (1.19–3.39); false discovery rate 
(FDR)-P=1.31×10–2]. In the Derivation#2 study, results were confirmed for the BRIP1 
‘GGG’ haplotype [OR, 0.53 (0.36–0.79); FDR-P=3.90×10–3]. In both Validation#1 and 
#2 studies, BRIP1 ‘AAA’ haplotype was significantly associated with an increased 
risk of HCC [OR, 1.71 (1.09–2.68); FDR-P=7.30×10–2; and OR, 6.45 (4.17–9.99); 
FDR-P=2.33×10–19, respectively]. Association between the BRIP1 locus and HCC risk 
suggests that impaired DNA mismatch repair might play a role in liver carcinogenesis, 
among patients with HCV- or HBV-related liver disease.
INTRODUCTION
Hepatocellular carcinoma (HCC) is the commonest 
primary malignant tumor of the liver. It is the fifth most 
common cancer in men and the seventh in women, and 
it ranks third in annual cancer mortality rates worldwide 
[1, 2]. Infection with hepatitis C virus (HCV) or hepatitis 
B virus (HBV), alcoholic liver disease, and nonalcoholic 
fatty liver disease are the most dominant risk factors for 
HCC development [2]. The highest incidence rates of HCC 
occur in developing countries, such as sub-Saharan Africa, 
where the prevalence of chronic viral hepatitis is high [3]. 
The molecular mechanisms of HCC carcinogenesis are 
still not fully understood and are different according to 
their origins [4, 5]. HCC risk factors induce malignant 
transformation of hepatocytes by increasing cellular 
turnover leading to multiple genetic alterations such 
as chromosomal instability with point mutations and 
deletions causing the activation or inactivation of proto-
oncogenes or tumor suppressor genes, respectively [5]. 
HCV- and HBV-related HCC develop in an environment 
of ongoing inflammation and cell injury, both leading to 
increased cell turnover and liver fibrosis [6]. It has been 
shown that HCV can induce alteration of genes involved 
in deoxyribonucleic acid (DNA) mismatch repair (MMR) 
and cell cycle regulation [5, 7, 8]. The pathogenesis of 
HCC associated with alcoholic cirrhosis follows other 
mechanistic pathways that mainly involve oxidative stress 
in relation with ethanol metabolism and inflammation [9].
It has been suggested that genetic variants related 
to DNA repair could modulate HCC risk [10]. DNA 
repair systems are important parts of the cellular defense 
against a large variety of structural unrelated DNA lesions 
generated by both exogenous (ionizing radiation, strong 
alkylating agents) and endogenous DNA-damaging agents 
(viruses) [4, 11]. Genetic polymorphisms in DNA repair 
genes may influence individual variation in DNA repair 
capacity and may play an important role in carcinogenesis 
[12]. Several case-control studies evaluated the association 
between polymorphisms in DNA repair genes and HCC 
risk and have been inconclusive [13–19]. However, these 
studies have been limited to a single or a small number 
of genes and focused only on three DNA repair gene 
pathways, namely, base excision repair (BER), nucleotide 
excision repair (NER), and double-strand breaks repair 
(DSBR) [13–19].
Both candidate-gene and genome-wide association 
approaches have been used to identify common genetic 
variants associated with HCC risk [13–22]. Three 
genome-wide association studies (GWASs) conducted in 
Asian populations looked for genetic variants potentially 
associated with HCC in patient with HBV- or HCV-
induced chronic viral hepatitis [20–22]. These studies 
have failed to clarify the pathogenic pathways associated 
with HCC. One study was negative [21], a second study 
found intergenic variants outside any pathogenic pathway 
[22] and the third reported an association with a genetic 
variant on a gene involved in neurotransmission [20]. 
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Furthermore, no GWAS has been performed in European- 
or in African-ancestry populations.
We hypothesized that the inconclusive studies on 
the association between genetic variants in DNA repair 
genes and HCC risk may reflect limitations in study design 
and genetic variant selection. Using data from cirrhotic 
patients with and without HCC and non-cirrhotic patients 
with HCV- and/or HBV-related disease, we assessed the 
association between genetic variants on DNA repair genes 
and HCC risk using an in-house designed array. Through 
the same study design, we followed the derivation studies 
on European-ancestry patients by successful validation 
studies on African-ancestry patients that confirmed the 
strong implication of the BRIP1 locus in the genetic 
determinism of HCC risk in patients with HCV- and/or 
HBV-related liver disease.
RESULTS
Derivation #1 study among patients with 
alcoholic cirrhosis
On the 496 cirrhotic patients included in the study 
(Table 1), 355 had alcoholic cirrhosis (See Supplemental 
Table S1 in the supplementary appendix for patients’ 
characteristics). Among patients with alcoholic cirrhosis, 
112 had HCC and were compared with 243 HCC-
free patients. No haplotype block reached array-wide 
significance among the 253 haplotype blocks analyzed.
Derivation #1 study among patients with viral 
cirrhosis
Characteristics of patients with viral cirrhosis 
according to their HCC status are reported in Table 2. 
Patients with HCV-related cirrhosis did not differ from 
those with HBV-related cirrhosis regarding baseline 
characteristics (See Supplemental Table S2 in the 
supplementary appendix).
Among patients with viral cirrhosis, 56 HCC patients 
were compared with 85 HCC-free patients. Among the 253 
haplotype blocks tested for their association with HCC risk 
only one reached array-wide significance and was located 
in the BRIP1 locus (BRCA1 interacting protein C-terminal 
helicase 1; Gene ID: 83990; formerly known as BACH1 
or FANCJ) in the chromosome 17q23 (Chi-Squared SV 
Perm, P=5.00×10−4) (See Supplemental Table S3 in the 
supplementary appendix). The BRIP1 haplotype block 
included three exonic variants with two variants located 
in the exon 19 (rs4986765, p.Glu879= and rs4986764, 
p.Ser919Pro) and one variant located in the exon 20 
(rs4986763; p.Tyr1137=). These three variants were in 
strong LD within the BRIP1 haplotype block with D’ 
values ranging from 0.97 to 1. Among the three different 
haplotypes of the BRIP1 haplotype block, the ‘AAA’ 
haplotype (simultaneous occurrence of the minor allele 
for each one of the three BRIP1 variants) was associated 
with an increased risk of HCC (EM frequency in cases, 
38%; EM frequency in controls, 24%; odds ratio, 2.01; 
95% CI, 1.19 to 3.39; P=8.74×10−3; FDR-P=1.31×10−2). 
Conversely, the BRIP1 ‘GGG’ haplotype (simultaneous 
occurrence of the major allele for each one of the three 
BRIP1 variants) was associated with a decreased HCC risk 
(EM frequency in cases, 45%; EM frequency in controls, 
66%; odds ratio, 0.42; 95% CI, 0.26 to 0.69; P=5.09×10−4; 
FDR-P=1.53×10−3) (Table 3, Figure 1, and Supplemental 
Figure S1 in the supplementary appendix).
In the Derivation #1 study among patients with 
viral cirrhosis, harboring the minor allele for the BRIP1 
variant (rs4986764; p.Ser919Pro) conferred an increased 
risk of HCC (odds ratio, 2.32; 95% CI, 1.42 to 3.79; 
P=8.32×10−4) (Table 4).
In multivariate logistic regression analysis, the three 
BRIP1 variants were independently associated with HCC 
risk after adjusting for age, sex, body mass index, alcohol 
consumption, alanine aminotransferase level, disease 
duration of cirrhosis, viral cirrhosis etiology, and the top 
eigenvalue obtained from the primary component analysis 
in order to adjust for potential population admixture 
(rs4986763, adjusted OR, 2.52; 95% CI, 1.37 to 4.61; 
P=2.9×10−3; rs4986764, adjusted OR, 2.50; 95% CI, 1.36 
to 4.59; P=3.2×10−3; and rs4986765, adjusted OR, 2.18; 
95% CI, 1.17 to 4.06; P=1.4×10−2).
Using multivariate Cox proportional-hazards 
regression analysis, the three BRIP1 variants were 
independently associated with time to HCC occurrence 
after adjusting for age, sex, body mass index, alcohol 
consumption, aminotransferase level, viral cirrhosis 
etiology, and the top eigenvalue obtained from the 
primary component analysis in order to adjust for potential 
population admixture (rs4986763, adjusted HR, 1.62; 
95% CI, 1.06 to 2.47; P=2.6×10−2; rs4986764, adjusted 
HR, 1.60; 95% CI, 1.05 to 2.44; P=3.2×10−2; rs4986765, 
adjusted HR, 1.57; 95% CI, 1.03 to 2.42; P=3.8×10−2) 
(Figure 2).
Derivation #2 study
In the Derivation #2 study, BRIP1 haplotypes ‘AAA’ 
and ‘GGG’ had similar effect sizes for their association 
with HCC risk in comparison with those observed in 
Derivation #1 study (Table 3). Consistently, at the genetic 
variant level, harboring the minor allele for the BRIP1 
variant (rs4986764; p.Ser919Pro) conferred an increased 
risk of HCC (odds ratio, 1.83; 95% CI, 1.24 to 2.69; 
P=2.59×10−3) (Table 4). In post-hoc exploratory analysis, 
haplotype trend regression was carried out in order to 
estimate the influence of HCV genotype on the association 
between BRIP1 haplotypes and HCC phenotype in a subset 
of patients with available data from the Derivation#2 
study (23 cases from CiRCE and 970 controls from the 
ANRS Genoscan and Swiss Hepatitis C Cohort Studies). 
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2008 2005 to 2009 2008 2005 to 2009 2007 2005 to 2009 —
Age, years 60 54 to 68 65 59 to 72 58 52 to 65 <0.0001
Weight, kg 78 66 to 90 80 67 to 92 76 66 to 89 0.17
Height, m 1.70 1.65 to 1.76 1.71 1.65 to 1.77 1.70 1.65 to 1.76 0.62
BMI (kg/m²) 26.6 23.5 to 29.9 27.6 23.4 to 30.7 26.2 23.6 to 29.7 0.13
 n/N (%) 95% CI n/N (%) 95% CI n/N (%) 95% CI P-value†
Gender        
Female 128/496 (25.8) 21.9 to 29.7
29/168 
(17.3) 11.5 to 23.0 99/328 (30.2) 25.2 to 35.2 0.002
Male 368/496 (74.2) 70.3 to 78.1
139/168 
(82.7) 77 to 88.5 229/328 (69.8) 64.8 to 74.8 —
Alcohol 
consumption        
Yes 456/494 (92.3) 89.9 to 94.7
156/168 
(92.9) 88.9 to 96.8 300/326 (92.0) 89.1 to 95 0.86
No 38/494 (7.7) 5.3 to 10.1
12/168 
(7.1) 3.2 to 11.1 26/326 (8.0) 5 to 10.9 —
Smoking status        
Current 189/494 (38.3) 34 to 42.6
54/167 
(32.3) 25.2 to 39.5 135/327 (41.3) 35.9 to 46.6 0.06
Former 179/494 (36.2) 32 to 40.5
77/167 
(46.1) 38.5 to 53.7 102/327 (31.2) 26.1 to 36.2 0.002
Never 126/494 (25.5) 21.6 to 29.4
36/167 
(21.6) 15.3 to 27.9 90/327 (27.5) 22.7 to 32.4 0.16
Etiology of 
cirrhosis        
Alcohol 355/496 (71.6) 67.6 to 75.6
112/168 
(66.7) 59.5 to 73.9 243/328 (74.1) 69.3 to 78.9 ‡
HCV 115/496 (23.2) 19.5 to 26.9
42/168 
(25.0) 18.4 to 31.6 73/328 (22.3) 17.7 to 26.8 ‡
HBV 23/496 (4.6) 2.8 to 6.5
13/168 
(7.7) 3.7 to 11.8 10/328 (3.1) 1.2 to 4.9 ‡
HCV and HBV 
coinfection
3/496 
(0.6) 0 to 1.3
1/168 
(0.6) 0 to 1.8 2/328 (0.6) 0 to 1.46 ‡
NOTE. BMI: Body mass index; HCC: hepatocellular carcinoma; HCV: hepatitis C virus; HBV; hepatitis B virus; IQR: 
interquartile range.
* Mann-Whitney U test; † Chi-squared test; ‡ Proportions of cirrhosis etiologies have not been compared between cases 
and controls because patients were selected on the basis of this criterion.
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2007 2003 to 2009 2007 2003 to 2009 2007 2003 to 2008 0.34
Age, years 62 53 to 71 67 55 to 74 61 51 to 68 0.03
Weight, kg 74 65 to 84 71 62 to 84 75 67 to 85 0.11
Height, m 1.70 162 to 175 1.69 161 to 175 1.70 162 to 176 0.81
BMI (kg/m²) 25.3 23.0 to 29.1 24.4 21.8 to 28.7 26.2 23.8 to 29.5 0.07




2 1 to 7 2 0 to 7 2.000 1 to 7 0.17
 n/N (%) 95% CI n/N (%) 95% CI n/N (%) 95% CI P-value†
Gender        
Female 39/141 (27.7) 20.2 to 35.1 17/56 (30.4) 17.9 to 42.8 22/85 (25.9) 16.4 to 35.4 0.70
Male 102/141 (72.3) 64.9 to 79.8 39/56 (69.6) 57.2 to 82.1 63/85 (74.1) 64.6 to 83.6 —
Etiology of 
cirrhosis        
HCV 115/141 (81.6) 75.1 to 88 42/56 (75.0) 63.3 to 86.7 73/85 (85.9) 78.3 to 93.4 0.16




3/141 (2.13) 0 to 4.54 1/56 (1.79) 0 to 5.36 2/85 (2.35) 0 to 5.64 ‡
Alcohol 
consumption        
Yes 110/140 (78.6) 71.7 to 85.5 44/56 (78.6) 67.5 to 89.7 66/84 (78.6) 69.6 to 87.5 0.83
No 30/140 (21.4) 14.5 to 28.3 12/56 (21.4) 10.3 to 32.5 18/84 (21.4) 12.5 to 30.4 —
Smoking 
status        
Current 51/141 (36.2) 28.1 to 44.2 22/56 (39.3) 26.1 to 52.5 29/85 (34.1) 23.8 to 44.4 0.66
Former 50/141 (35.5) 27.5 to 43.5 15/56 (26.8) 14.8 to 38.8 35/85 (41.2) 30.5 to 51.9 0.12
Never 40/141 (28.4) 20.8 to 35.9 19/56 (33.9) 21.1 to 46.7 21/85 (24.7) 15.3 to 34.1 0.32
NOTE. HCC: hepatocellular carcinoma; ALAT: alanine aminotransferase; BMI: Body mass index; HCV: hepatitis C 
virus; HBV; hepatitis B virus; IQR: interquartile range.
* Mann-Whitney U test; † Chi-squared test; ‡ Statistical comparison not performed due low sample size.
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Table 3: Association between BRIP1 haplotypes and HCC risk in derivation (Derivation #1 and #2) and validation 

















Derivation #1 study (EUR)‡
HCC patients vs HCC-free cirrhotic patients with HBV- and/or HCV-related cirrhosis
Per block, P-value = 5.00×10−4
AAA 0.38 0.24 8.74×10−3 1.31×10−2 2.01 1.19 to 3.39
AAG 0.16 0.10 0.12 0.12 1.76 0.86 to 3.58
GGG 0.45 0.66 5.09×10−4 1.53×10−3 0.42 0.26 to 0.69
Derivation #2 study (EUR)§
HCC patients vs HCC-free and cirrhosis-free patients with HCV infection
Per block, P-value = 1.93×10−3
AAA 0.38 0.30 0.08 0.08 1.43 0.96 to 2.13
AAG 0.16 0.09 9.05×10−3 1.36×10−2 2.00 1.18 to 3.39
GGG 0.45 0.60 1.30×10−3 3.90×10−3 0.53 0.36 to 0.79
Validation #1 study (AFR)‖
HCC patients vs HCC-free cirrhotic patients with HBV- or HCV-related cirrhosis
Per block, P-value = 0.08
AAA 0.28 0.18 1.82×10−2 7.30×10−2 1.71 1.09 to 2.68
AAG 0.13 0.18 0.12 0.23 0.66 0.40 to 1.11
GGG 0.58 0.63 0.35 0.47 0.84 0.57 to 1.22
Validation #2 study (AFR)¶
HCC patients vs HCC-free and cirrhosis-free patients with HBV- and/or HCV infection
Per block, P-value = 4.47×10−21
AAA 0.28 0.06 5.82×10−20 2.33×10−19 6.45 4.17 to 9.99
AAG 0.13 0.30 3.81×10−8 7.63×10−8 0.34 0.23 to 0.50
GGG 0.58 0.62 0.33 0.33 0.86 0.65 to 1.16
NOTE. HCC: hepatocellular carcinoma; EM: haplotype frequency using the expectation/maximization algorithm; FDR: 
false discovery rate; 95% CI: 95% confidence interval; EUR: Europeans, AFR: Africans; JVH: Jean Verdier Hospital 
cohort.
* BRIP1 haplotypes are based on the three BRIP1 variants studied sorted by increasing genomic position (rs4986763, 
rs4986764, rs4986765)
† Odds ratio for patients harboring the specified haplotype
‡ Derivation #1: HCC patients from the CiRCE study (n=56) were compared with HBV- and/or HCV-induced cirrhosis but 
without HCC from the CiRCE study (n=85)
§ Derivation #2: HCC patients from the CiRCE study (n=56) were compared with patients with HCV-related chronic liver 
disease from two European cohorts (ANRS Genoscan study group, n=398; Swiss Hepatitis C Cohort Study, n=572)
‖ Validation #1: HCC patients from the Jean Verdier Hospital cohort (n=136) were compared with HCC-free cirrhotic 
patients (Jean Verdier Hospital cohort) (n=99)
¶ Validation #2: HCC patients from the Jean Verdier Hospital cohort (n=136) were compared with HBV- and/or HCV-
infection from the Benin-Togo cohort (n=305)
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Figure 1: A. Overview on the study design; B. Manhattan plot reporting the association between haplotype blocks on DNA repair genes 
and hepatocellular carcinoma risk in the Derivation #1 study among patients with viral cirrhosis. Association results of the single-variant 
analysis (−Log10 P) are plotted against genomic position (GRCh37 hg19); C. Forest plots showing the effect size of associations between 
HHC risk and BRIP1 haplotypes in derivation (Derivation #1 and #2) and validation (Validations #1 and #2) studies among patients 
with viral hepatitis. For each analysis, the odds ratio of the association is reported with the 95% confidence interval (solid line) [EUR: 
Europeans; AFR: Africans; HCC: hepatocellular carcinoma; HBV: hepatitis B virus; HCV: hepatitis C virus; Derivation #1: HCC patients 
from the CiRCE study (n=56) were compared with HBV- and/or HCV-induced cirrhosis but without HCC from the CiRCE study (n=85); 
Derivation #2: HCC patients from the CiRCE study (n=56) were compared with patients with HCV-related chronic liver disease from two 
European cohorts (ANRS Genoscan study group, n=398; Swiss Hepatitis C Cohort Study, n=572); Validation #1: HCC patients from the 
Jean Verdier Hospital cohort (n=136) were compared with HCC-free cirrhotic patients (Jean Verdier Hospital cohort) (n=99); Validation 
#2: HCC patients from the Jean Verdier Hospital cohort (n=136) were compared with HBV- and/or HCV-infection from the Benin-Togo 
cohort (n=305)].
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Consistently, the BRIP1 ‘GGG’ haplotype was still 
significantly associated with a reduced risk of HCC risk 
(odds ratio, 0.18; 95% CI, 0.05 to 0.59; P=4.16×10−3). 
HCV genotype did not influence this association (P=0.26).
Validation #1 study
In the Validation #1 study on African ancestry 
patients, 136 HCC patients with viral-related cirrhosis 
from the JVH cohort were compared with 99 HCC-free 
patients with HBV- or HCV-related cirrhosis from the 
JVH cohort. Among cirrhotic patients, the proportions of 
HCV- and HBV-related cirrhosis were 57.4% (n=135) and 
42.6% (n=100), respectively and males were predominant 
(65.1%, n=153). The BRIP1 haplotype block was 
significantly associated with HCC risk. The BRIP1 ‘AAA’ 
haplotype was associated with an increased risk of HCC 
(EM frequency in cases, 28%; EM frequency in controls, 
18%; odds ratio, 1.71; 95% CI, 1.09 to 2.68; P=1.82×10−2; 
FDR-P=7.30×10−2) (Table 3). At the genetic variant level, 
Table 4: Association between BRIP1 genetic variants and HCC risk in derivation (Derivation #1 and #2) and 
validation (Validation #1 and #2) studies among patients with viral hepatitis














Derivation #1 study (EUR)‡
HCC patients vs HCC-free cirrhotic patients with HBV- and/or HCV-related cirrhosis
rs4986763 17 59760996 p.Tyr1137= 4.96×10−4 1.49×10−3 2.42 1.48 to 3.97 0.55 0.34
rs4986764 17 59763347 p.Ser919Pro 8.32×10−4 1.25×10−3 2.32 1.42 to 3.79 0.55 0.34
rs4986765 17 59763465 p.Glu879= 1.06×10−2 1.06×10−2 2.01 1.19 to 3.39 0.38 0.24
Derivation #2 study (EUR)§
HCC patients vs HCC-free and cirrhosis-free patients with HCV infection
rs4986763 17 59760996 p.Tyr1137= 1.86×10−3 5.59×10−3 1.88 1.27 to 2.76 0.55 0.40
rs4986764 17 59763347 p.Ser919Pro 2.59×10−3 3.89×10−3 1.83 1.24 to 2.69 0.55 0.40
rs4986765 17 59763465 p.Glu879= 0.09 0.09 1.41 0.95 to 2.10 0.38 0.30
Validation #1 study (AFR)‖
HCC patients vs HCC-free cirrhotic patients with HBV- or HCV-related cirrhosis
rs4986763 17 59760996 p.Tyr1137= 0.45 0.45 1.17 0.81 to 1.71 0.41 0.37
rs4986764 17 59763347 p.Ser919Pro 0.34 0.51 1.21 0.83 to 1.77 0.40 0.36
rs4986765 17 59763465 p.Glu879= 2.19×10−2 6.56×10−2 1.69 1.08 to 2.63 0.28 0.19
Validation #2 study (AFR)¶
HCC patients vs HCC-free and cirrhosis-free patients with HBV- and/or HCV infection
rs4986763 17 59760996 p.Tyr1137= 0.33 0.33 1.16 0.86 to 1.55 0.41 0.38
rs4986764 17 59763347 p.Ser919Pro 0.17 0.26 1.23 0.92 to 1.65 0.40 0.36
rs4986765 17 59763465 p.Glu879= 6.42×10−18 1.93×10−17 6.18 4.03 to 9.49 0.28 0.06
NOTE. Chr: chromosome; FDR: false discovery rate; OR: odds ratio; 95% CI: 95% confidence interval; MAF: minor 
allele frequency.
* According to the GRCh37 assembly
† Odds ratio for the minor allele
‡ Derivation #1: HCC patients from the CiRCE study (n=56) were compared with HBV- and/or HCV-induced cirrhosis but 
without HCC from the CiRCE study (n=85)
§ Derivation #2: HCC patients from the CiRCE study (n=56) were compared with patients with HCV-related chronic liver 
disease from two European cohorts (ANRS Genoscan study group, n=398; Swiss Hepatitis C Cohort Study, n=572)
‖ Validation #1: HCC patients from the Jean Verdier Hospital cohort (n=136) were compared with HCC-free cirrhotic 
patients (Jean Verdier Hospital cohort) (n=99)
¶ Validation #2: HCC patients from the Jean Verdier Hospital cohort (n=136) were compared with HBV- and/or HCV-
infection from the Benin-Togo cohort (n=305)
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Figure 2: Cumulative probability of hepatocellular carcinoma occurrence among patients with viral cirrhosis in the 
CiRCE study according to BRIP1 variants. Cumulative probability of hepatocellular carcinoma occurrence according to BRIP1 
variants [rs4986763 (A), rs4986764 (B), and rs4986765 (C)] among patients with viral cirrhosis using multivariate Cox proportional-
hazards regression analysis; GG: Major homozygous genotype, GA: Heterozygous genotype, AA: Minor homozygous genotype; (D) 
Structure of the BRIP1 gene. The BRIP1 gene codes for the BRIP1 protein which comprises DNA Helicase domains (0, I, Ia, II, III, IV, V, 
and VI), a BLM binding domain, and MRE11 binding domain. Genomic positions of the three BRIP1 variants found in association with 
hepatocellular cancer risk among patients with viral cirrhosis are indicated (adapted from references [24, 27, 58]).
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on the three BRIP1 variants tested for their association 
with HCC risk, only rs4986765 was significantly 
associated with HCC risk (odds ratio, 1.69; 95% CI, 1.08 
to 2.63; P=2.19×10−2; FDR-P=6.56×10−2) (Table 4).
Validation #2 study
In the Validation #2 study on African ancestry 
patients, 136 HCC patients with viral-related cirrhosis 
from the JVH cohort were compared with 305 HCC-
free and cirrhosis-free patients with HBV- and/or HCV 
infection recruited in Benin-Togo cohort. Consistently 
with results from the Validation #1 study, the BRIP1 
‘AAA’ haplotype was associated with an increased risk 
of HCC (EM frequency in cases, 28%; EM frequency 
in controls, 6%; odds ratio, 6.45; 95% CI, 4.17 to 9.99; 
P=5.82×10−20; FDR-P=2.33×10−19) (Table 3). At the 
genetic variant level, on the three BRIP1 variants tested 
for their association with HCC risk, only rs4986765 was 
significantly associated with HCC risk (odds ratio, 6.18; 
95% CI, 4.03 to 9.49; P=6.42×10−18; FDR-P=1.93×10−17) 
(Table 4).
DISCUSSION
This is the first study that has performed a 
comprehensive assessment of DNA repair genes variants 
and their influence on HCC risk in both European- and 
African-ancestry populations. We demonstrated that the 
BRIP1 locus was strongly associated with HCC risk in 
patients with HBV- and/or HCV-induced liver disease 
even after adjusting for age, sex, body mass index, 
alcohol consumption, aminotransferase level, disease 
duration, viral cirrhosis etiology, and potential population 
admixture. BRIP1, also known as BACH1 or FANCJ, is an 
essential tumor suppressor gene based on the identification 
of clinically relevant BRIP1 mutations in several cancers 
like hereditary breast and ovarian cancers and childhood 
cancer syndrome [23]. BRIP1 encodes a 1249 residue 
nuclear protein (BRIP1) which collaborates with a number 
of DNA metabolizing proteins implicated in DNA damage 
detection and repair, and plays an important role in cell 
cycle checkpoint control [24]. BRIP1 is a DNA-dependent 
ATPase and a 5'-to-3' DNA helicase that achieves its 
cancer suppression function and DNA double-strand break 
repair through direct interaction with the highly conserved, 
C-terminal BRCT (BRCA1 C-Terminal domain) protein 
domain repeats of the tumor suppressor BRCA1 [24, 
25]. The N-terminal 888-residue structure of BRIP1 
shows strong homology with the catalytic and nucleotide 
binding domain of DEAH helicase family members [26, 
27]. Abnormal BRIP1 function contributes to tumor 
induction [25]. Indeed, mutations within the BRCT repeats 
on BRCA1 disrupt its interaction with BRIP1 and lead to 
defects in DNA repair thereby resulting in several forms 
of cancers [25]. In two patients with early-onset breast 
cancer, mutations in the BRIP1 coding regions resulted 
in a defective helicase activity [25]. Hence, both absence 
of the BRIP1 DNA helicase function or BRIP1-BRCA1 
interaction can induce defects in several aspects of the 
DNA damage response [23].
Phosphorylation of the BRIP1 protein mediates 
interactions that promote repair and check point responses 
[24]. Phosphorylation of the Serine residue at position 990 
is essential for BRIP1 binding to the tandem C-terminal 
BRCT motifs of BRCA1 [28] (Figure 2D). Loss of the Ser-
990 phosphorylation limits homologous recombination 
repair of double strand break [24, 29]. The BRCA1-
interacting region of BRIP1 extends from residues 976 
to 1006 that corresponds to exons 19 and 20 (Figure 
2D) [24]. In our study, the three BRIP1 variants that 
we found in association with HCC risk are proxy to the 
BLM (Bloom’s syndrome protein) domain that overlaps 
with the BRIP1 Ser-990 phosphorylation site, raising the 
hypothesis that the protein interaction of BRIP1 with BLM 
is affected by phosphoSer-990 [24, 30].
In our study, the BRIP1 variant rs4986763 is located 
in the MRE11 protein binding domain. MRE11 is a double 
strand break repair protein that functions with or in 
parallel with BRCA1 in order to localize BRIP1 to sites of 
DNA breaks [24, 31]. MRE11 and its associated nuclease 
activity are necessary for efficient BRIP1 recruitment to 
laser-induced double strand break [24, 31].
The BRIP1 gene is mutated in patients with Fanconi 
anemia (FA), a progressive bone marrow failure disorder, 
which is an autosomal recessive disease associated with an 
abnormal response to DNA damage [24, 32]. The BRIP1 
protein operates in the FA pathway of interstrand cross-
link repair and contributes to homologous recombination 
[24]. In patients with FA, it has been calculated that the 
estimated cumulative probability of development of a solid 
tumor was 76% by the age of 45 years [32]. Importantly, 
in these patients, the median age for cancer was 16, 
compared with 68 in the general population [32]. Patients 
with FA, a BRIP1-related disease, are prone to liver tumors 
[33]. In a systematic review on FA patients the calculated 
prevalence rate of liver tumors was 3% [32], thus 10-fold 
higher when compared with patients with chronic HBV 
infection (0.28%) [34]. Altogether, these data support the 
leading role of BRIP1 in liver carcinogenesis.
In our study, among the three BRIP1 variants 
associated with HCC risk, two (rs4986764 and rs4986765) 
are located in the vicinity of a MutLα interaction domain 
suggesting their potential implication through the BRIP1/
MutLα pathway [27]. BRIP1 is physically linked to 
MutLα complex (a heterodimer of MLH1 and PMS2), 
one of the main players in DNA mismatch repair (MMR) 
[27, 35]. BRIP1 interacts with MLH1 through its helicase 
domain [35]. BRIP1-MutLα interaction, but not BRIP1-
BRCA1 interaction, is essential for the establishment 
of an MLH1-dependent interstrand crosslink-induced 
repair function of BRIP1 [27, 35]. Interestingly, BRIP1 
rs4986764 (p.Ser919Pro) is located in the vicinity of 
the DNA helicase domain VI (Figure 2) suggesting 
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a potential functional consequence of this missense 
variant on the alteration of BRIP1 signaling pathway. 
Immunohistochemistry-based approach helps identifying 
tumors exhibiting microsatellite instability when staining 
is negative for MLH1, PMS2, MSH2 and/or MSH6 
antibodies [36]. In this setting, immunohistochemistry 
is recommended as a screening method for Lynch 
syndrome among patients with endometrial cancer [37]. 
Using immunohistochemistry assay, BRIP1 expression 
was observed to be reduced in cervical adenocarcinoma 
compared with normal cervix tissue and was correlated 
with unfavorable outcome including lymph node 
metastases [38]. No data were reported on HCC patients.
Three GWAS conducted in Asian populations 
looked for genetic variants potentially associated with 
HBV- and HCV-related HCC risk but failed to decipher 
the pathogenic pathways associated with HCC [20–22]. 
The first GWAS compared 355 chronic HBV carriers with 
HCC and 360 chronic HBV carriers without HCC, all 
of Chinese ancestry, through genotyping 440,794 SNPs 
and identified one intronic SNP (rs17401966) in KIF1B 
(kinesin family member 1B) on chromosome 1p36.22 
that was associated with HBV-related HCC (joint OR, 
0.61) [20]. The KIF1B gene encodes a motor protein that 
transports mitochondria and synaptic vesicle precursors 
and mutations in this gene have been associated with 
Charcot-Marie-Tooth disease [39]. In the second GWAS, 
95 HBV-infected HCC patients and 97 HBV-infected 
patients without HCC were compared using the Illumina 
Human610-Quad BeadChip [22]. Four SNPs (rs12682266, 
rs7821974, rs2275959, rs1573266) at chromosome 8p12 
were associated with HCC risk with ORs ranging from 
1.31 to 1.39 [22]. These four variants are not within a 
gene or within its vicinity. To identify potential genetic 
susceptibility factors in association with HCV-induced 
HCC, 721 individuals with HCV-induced HCC and 2,890 
HCV-negative controls of Japanese origin were compared 
in the third GWAS using 432,703 autosomal SNPs [21]. 
No variant was associated with HCC risk [21]. These 
three GWAS used a hypothesis-free tag-SNP approach 
and did not reveal any association with the BRIP1 locus 
or its vicinity. Many reasons can be advanced to explain 
this fact. First, GWAS genotyping platforms are designed 
to exploit linkage disequilibrium patterns which are 
population specific [40]. For instance, many variants 
associated with breast cancer in European-ancestry women 
showed only a weak or no association with breast cancer 
in other ethnic groups [41]. This highlights the importance 
of transethnic genome-wide association studies across 
worldwide populations of ethnically diverse genetic 
ancestries [42]. Interestingly, in our study, the minor 
allele frequencies of the top variant in the replication 
study on Africans (rs4986765) differed between African 
(9%) and European controls (30%). We used data from 
the 1000 Genomes Phase 1 v3 project for calculating the 
Fixation index (FST) between Europeans and Africans 
on the whole set of 714,058 variants including the 
37 variants on BRIP1 [43, 44]. The median FST index 
between European and African subpopulations was 0.004 
and the FST index for rs4986765 was 0.2196, which was 
highly suggestive of directional selection (upper outlier 
threshold, 0.0466) (Supplemental Table S4). Consistently, 
in the Exome Aggregation Consortium (ExAC; http://
exac.broadinstitute.org/) database on 60,706 unrelated 
individuals, the ‘A’ allele of rs4986765 had a frequency of 
33.52% in Europeans (Non-Finnish) versus only 9.52% in 
Africans. Hence, the data from ExAC support our findings 
in control populations from both derivation and validation 
studies. Second, the genomic coverage of hypothesis-
free tag-SNP approach used in GWAS genotyping arrays 
do not cover all common variants, and thus leading to 
false-negative results [45]. At the opposite, the custom 
array used in our study intentionally focused on DNA 
repair genes, thus increasing the a priori probability of 
identifying genetic variants associated with risk of HCC 
on DNA repair genes.
Our study confirms the pathogenic cleavage 
between HCC related to chronic viral hepatitis and those 
occurring in patients with alcoholic cirrhosis [46]. A recent 
meta-analysis of individual participant data revealed that 
the genetic association between a missense variant of 
PNPLA3 (rs738409) and HCC risk was more pronounced 
in patients with alcoholic liver disease in comparison with 
patients with chronic HCV infection [46]. In our study, 
BRIP1 variants were associated with HCC risk in patients 
with viral cirrhosis but not among those with alcoholic 
cirrhosis. Furthermore, the validation study on African 
populations —with a less dominant etiology of alcoholic 
cirrhosis— found the same results.
Our study has several strengths. First, we performed 
a comprehensive assessment of DNA repair genes variants 
through a custom-array approach based on exhaustive 
literature and mechanistic reviews. Second, we reported 
the first association study on genetic variants associated 
with HCC risk in European-ancestry populations. Third, 
we demonstrated the potential implication of the BRIP1 
gene in HCV- and HBV-induced liver carcinogenesis in 
both European- and African-ancestry populations.
We need to acknowledge limitations. First, the 
GoldenGate Assay applies stringent requirements to the 
quality of genetic variants and may generate missing data. 
It is the reason why we applied stringent quality control 
procedure by removing samples and SNPs with call rates 
under 90%. It should be noted that genotypes determined 
with the Illumina® GoldenGate® platform were highly 
concordant with those determined with the standard Sanger 
sequencing approach for all the three BRIP1 variants found 
in association with HCC, in our study (data not shown). 
Second, among patients with viral cirrhosis, those with 
HCC were 6 years older than controls. This age difference 
between cases and controls is inherent to case-control 
design of the study. Indeed, HCC is unusual before the age 
of 40 years and reaches its peak prevalence at the age of 70 
years [2]. Nevertheless, BRIP1 variants were independently 
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associated with HCC risk even after adjusting for age and 
cirrhosis duration. Third, we have not performed functional 
studies for evaluating the influence of BRIP1 variants on 
the inactivation of the FA pathway in HCC; however, in 
consistence with our results, a previous report showed 
genetic inactivation of the FA pathway in HuH-7 HCC cell 
lines [47]. Fourth, cirrhotic patients without HCC could 
be still at risk for developing HCC after the end of our 
study and this may lead to a misclassification bias. In fact, 
BRIP1 variants were associated with HCC risk even after 
adjusting for cirrhosis duration in logistic regression analysis 
and also in Cox's time-dependent proportional hazards 
regression analysis. Furthermore, we have performed genetic 
association studies comparing HCC patients with non-
cirrhotic HCC-free patients with HCV and/or HBV infection 
and confirmed the association between the BRIP1 locus and 
HCC risk. Finally, BRIP1 variants could have phenotype 
expression at the pathological or radiological level; however, 
these data were not fully available in our study to allow us 
studying genotype-phenotype correlations. Future studies 
should assess the influence of BRIP1 variants at the clinical, 
pathological, and molecular levels.
Our study should deserve further interest for 
evaluating BRIP1 genotype as a predictor of efficacy in 
forthcoming innovative therapeutics of HCC that will 
target pathways related to FA [48]. Among these drugs, 
Poly(adenosine diphosphate ribose) polymerase (PARP) 
inhibitors have been shown to be effective in cancer 
patients with mutations in homologous recombination 
repair genes, including BRIP1 [49, 50]. In vitro 
PARP inhibition using ABT-888 (veliparib), an orally 
bioavailable PARP inhibitor, was directly effective on 
HCC cell lines and enhanced their radiosensitivity [51]. 
A phase 2 trial found an 88% response rate to olaparib, 
another PARP inhibitor, in patients with castration-
resistant prostate cancers showing defects in DNA-repair 
genes, including FA pathway genes [52]. A major finding 
of this trial was that the optimal response to olaparib was 
observed in patients whose tumors had monoallelic ATM 
aberrations with mutations affecting the kinase catalytic 
domain [52]. Nevertheless, BRIP1 role as a key player in 
carcinogenesis and as a therapeutic target remains to be 
specifically assessed in HCC.
In conclusion, our results provide evidence for the 
potential implication of BRIP1, a master gene of DNA 
mismatch repair, on HCC risk in both European- and 
African-ancestry populations. It sheds new light on the 
genetic architecture of liver carcinogenesis in the setting of 
chronic viral hepatitis. Our results suggest investigating in 
experimental models the BRIP1 phosphorylation pathway 
and its interaction with BLM as a possible mechanisms 
of liver carcinogenesis. Previous preclinical studies have 
showed that PARP inhibition is a potentially promising 
therapeutic strategy for HCC. Our data suggest that the 
BRIP1 genotyping should be used to predict the efficacy 
of forthcoming trials of HCC treatments that will target 
this pathway.
MATERIALS AND METHODS
Genetic variant selection for the ‘DNA repair 
genes’ custom array
Based on an exhaustive review of the literature, a 
total of 94 genes involved in DNA repair and genomic 
stability were included in the ‘DNA repair genes’ custom 
array (Supplemental Table S5). Selection criteria, 
validation process, and detailed array design are available 
in Supplementary Methods (See supplementary appendix).
Study design and primary aim
We performed four case-control studies on 2,006 
European- (Derivation#1 and #2 studies) and African-
ancestry (Validation#1 and #2 studies) patients originating 
from several cohorts [CiRCE study (n=496), ANRS 
Genoscan study (n=398), Swiss Hepatitis C Cohort Study 
(n=572), Jean Verdier Hospital cohort (n=235), Benin-
Togo cohort (n=305)] using an in-house designed array 
encompassing 94 genes on eight DNA repair pathways. 
The full description of the four case-control studies is 
reported in Supplementary Methods (See supplementary 
appendix). In both Derivation #1 and Validation #1 
studies, HCC patients were compared with HCC-free 
cirrhotic patients. In both Derivation #2 and Validation 
#2 studies HCC patients were compared with HCC-free 
cirrhosis-free patients with HCV- or HBV-related liver 
disease. An overview of the study design is reported in 
Figure 1. The aim of the study was to look for potential 
genetic determinants associated with HCC risk through 
a fine mapping of genetic variants on DNA repair genes 
among patients with alcohol- or viral-induced liver 
disease.
Genotyping and quality controls
Genomic DNA was extracted from frozen 
white blood cells using the Nucleon BACC3 kit (GE 
Healthcare, France) according to the manufacturer’s 
instructions. Extracted DNA was dissolved in 200 
μL Tris-HCl buffer (10 mmol/L, pH 8.0) containing 
1 mmol/L EDTA and stored at -20°C until use. DNA 
concentrations were measured by using PicoGreen 
dSDNA quantification kit (Invitrogen, Carlsbad, CA, 
USA). Genotyping of all samples was performed with 
a total of 250 ng of genomic DNA using the Illumina 
BeadArray platform and GoldenGate Assay (Illumina 
Inc., San Diego, CA, USA) following the manufacturer’s 
protocol [53]. This system uses a high-density 
BeadArray technology in combination with an allele-
specific oligonucleotide extension, adapter ligation and 
amplification assay protocol. Briefly, biotinylated DNA 
was immobilized on paramagnetic beads and the pooled 
SNP-specific oligonucleotides in the OPA were annealed 
on the DNA. This hybridization step is followed by 
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an extension and ligation step, connecting one of the 
allele-specific oligo with the locus-specific oligo to 
generate DNA templates which were amplified using 
universal fluorescently-labelled primers. PCR products 
are annealed to an array composed of beads carrying 
oligonucleotides complementary to the IllumiCode 
sequences in the locus-specific oligos that are used 
for recognition of each SNP site. The fluorescence 
of an array matrix carrying Cy3- and Cy5- labeled 
beads were generated with the two-channel scanner. 
Hybridization data intensity processing, clustering and 
genotype calling were performed using the genotyping 
module in the BeadStudio 2 software (Illumina, 
USA). We followed the STREGA recommendations 
(STrengthening the REporting of Genetic Association 
Studies, http://www.med.uottawa.ca/public-health-
genomics/web/eng/strega.html) and used the GRCh37 
Genome Reference Consortium Human genome build 
37 as the reference assembles of human genome for 
mapping variants position. In the validation study, 
BRIP1 variants were genotyped using high-resolution 
melting analysis (See Supplemental Methods in the 
supplementary appendix).
Genotyping quality controls were performed before 
statistical analysis. All genetic variants with a call rate 
<90%, a minor allele frequency <1%, and those with a 
deviation from Hardy-Weinberg equilibrium (Fishers’ 
exact P-value <10−4) were removed before the analysis. 
All participants included in the study had sample call 
rate >90%. We assessed duplicated samples and those 
showing cryptic relatedness by calculating identity-by-
descent (IBD). By estimating the probability of sharing 
zero, one, or two alleles for any two individuals as P(Z=0), 
P(Z=1), and P(Z=2), respectively, a proportion of IBD was 
calculated using the following formula: PI-HAT = PI = 
P(Z=1)/2 + P(Z=2). PI-HAT value >0.99 was considered 
to be indicative of duplicate samples and PI-HAT 
threshold >0.2 was used to suggest cryptic relatedness. No 
sample was removed after IBD quality control. In order 
to identify ancestry outliers and population stratification, 
PCA on genomic data was performed on the study 
samples merged with 1kG project populations (AFR, 
AMR, ASN, and EUR) as reference populations [54]. 
Eigenvalues were calculated assuming an additive genetic 
model. Inspecting the first ten principal components, we 
identified 5 population outliers from the initial study and 
who have been excluded from subsequent analyses (See 
Supplemental Figure S2 in the supplementary appendix).
Statistical analysis
All quantitative variables are described as 
medians and percentiles [Interquartile range (IQR), 
25–75th percentile]. All proportions are expressed as 
percentages with 95% confidence intervals (95% CI). The 
comparison of continuous variables between subgroups 
was performed using the Mann-Whitney U test. Due to 
the relatively low sample size in the Validation #1 study 
we performed haplotype association tests approach using 
a moving window with a dynamic width of 10 kb. The 
association was calculated on a ‘per block’ basis using 
the Chi-squared test and multiple testing correction was 
carried out using single value permutations approach 
with 10.000 permutations. We estimated the haplotype 
frequencies using the expectation/maximization (EM) 
algorithm with a maximum EM iterations of 50 and an 
EM convergence tolerance of 0.0001 [55]. In post-hoc 
exploratory analysis, haplotype trend regression was 
carried out in order to estimate the influence of HCV 
genotype on the association between genetic variants and 
HCC phenotype in a subset of patients with available data 
from the Derivation#2 study. Genetic variants located 
in the top significant haplotype block were tested for 
their association with HCC risk in subsequent analyses. 
The comparison of genetic variant frequencies between 
patients with HCC and non-HCC subjects was carried out 
using the Fisher’s exact test for the allelic model with false 
discovery rate (FDR) for multiple testing correction since 
this method has been shown to be more powerful than the 
Bonferroni method, maintaining a false positive rate close 
to the nominal level [56]. Linkage disequilibrium pairwise 
analysis was performed using a matrix output for both the 
expectation-maximization (EM) algorithm and composite 
haplotype method (CHM) and D’ value [57]. Significant 
genetic variants were tested for their association with 
HCC risk in multivariate analysis using logistic regression 
and Cox proportional-hazards regression. Results were 
expressed as odds ratios (ORs) and hazard ratios (HRs) 
with their 95% CI, respectively. Multivariate analyses 
were performed using MedCalc for Windows, version 
16.1 (MedCalc Software, Ostend, Belgium) on the basis 
of a two-sided type I error with an alpha level of 0.05. 
All quality control and genotypic analyses were performed 
using SNP & Variation Suite (SVS) 8.4.3 (Golden Helix, 
Inc. Bozeman, MT, USA).
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